Level 7 Monash Health Translation Precinct Translational Research Facility Hudson Institute of Medical Research Melbourne Australia
|
|
- Barrie Cameron
- 6 years ago
- Views:
Transcription
1 Level 7 Monash Health Translation Precinct Translational Research Facility Hudson Institute of Medical Research Melbourne Australia Monash Health Translation Precinct: A partnership of Monash University, Hudson Institute of Medical Research and Monash Health.
2 2 Executive Summary and Background The Monash Health Translation Precinct (MHTP) brings together the largest health service in Victoria, Monash Health, with the largest university in Australia, Monash University, and the world-renowned Hudson Institute of Medical Research, to translate innovative scientific research into clinical practice. Together, they are a major contributor to Monash Partners Academic Health. United in the vision to be world leaders in translational research, MHTP partners have created a unique environment, which thematically co-locates our research and facilities at Monash Medical Centre (Figure 1). The MHTP s Translational Research Facility (TRF) is a purpose-built research space designed to drive research-based healthcare and provides a unique site for multidisciplinary, translational medical research in partnership with commercial entities such as Miltenyi Biotec. Recently launched, the $84 million, six-storey MHTP-TRF hosts a centrally positioned, Technology Platform floor with state-of-the-art capabilities to underpin research excellence and clinical translation. On this flagship floor we have co-located medical genomics, cell therapies, bioinformatics, mass spectrometry and micro-imaging; and together with histology, flow cytometry, animal model and biobanking capabilities, they create an integrated network of world-class capabilities. Our MHTP Technology Platforms are also closely affiliated with the extensive Monash Technology Research Platforms (MTRP) located at Monash University. The Technology Platform floor is ideally positioned within the MHTP-TRF between the Clinical Trials floor, the Ritchie Centre (specializing in the health of women and babies), the cancer research floor and a translational research floor in which Cartherics Pty Ltd is located. The fully-integrated Clinical Trials floor contains eight clinical beds and 21 chairs, is available 24/7 and is dedicated and increasingly accessed to a suite of rapidly expanding Phase 1 and Phase 2-4 trials. Importantly, the MHTP-TRF is directly linked by bridge connections to the clinical departments of Monash Health and to the Hudson Institute of Medical Research laboratories. The 7 th floor is occupied by companies involved in translation of discoveries to the clinic. Cartherics Pty Ltd are developing immune stem cell therapeutics for the treatment of human cancer. The focus is on an off the shelf product that includes gene edited chimeric antigen receptor expression in cytotoxic T cells derived from induced pluripotent stem (ips) cells and selected TCR expression of key tumor antigens. Further exciting developments, and integrated alongside the MHTP-TRF, is the $250 million, 239 bed Monash Children s Hospital scheduled to open in early Creating Australia s third largest children s hospital, the Ritchie Centre is a major research partner of Monash Children s. The Ritchie Centre and the MHTP are also strategically positioned more broadly within the South East Melbourne Innovation Precinct, which includes the Australian Synchrotron (with its medical beamline), Monash Biomedical Imaging, the Commonwealth Scientific and Research Organisation (CSIRO) and the Melbourne Centre for Nanofabrication (Figure 2). The MHTP is perfectly poised to embark on an exciting new era of translational cell therapy research as part of the newly launched Translational Research Facility.
3 3 Figure 1. Monash Health Translation Precinct (MHTP) has established the $84 million MHTP Translational Research Facility (TRF) and $250 million Monash Children s Hospital. The clinical departments (blue) are directly connected to research areas (orange) and the new MHTP-TRF (green). Figure 2. South East Melbourne Innovation Precinct hosts the Australian Synchrotron, CSIRO s largest research and development site, and Monash University, Australia s largest university. Monash University also hosts an array of national facilities, including the Monoclonal Antibody Technology Facility, the Australian Regenerative Medicine Institute and Melbourne Centre of Nanofabrication.
4 4 Monash Health Translation Precinct (MHTP) MHTP is a partnership between: Monash Health Victoria s largest public health service providing integrated care across the entire lifespan. Hudson Institute of Medical Research Improving global wellbeing through excellence in medical research and clinical application. Monash University Australia s l a r g e s t u n i v e r s i t y w i t h a n i n t e r n a t i o n a l r e p u t a t i o n f o r innovative health research. MHTP is also a critical component of Monash Partners Academic Health Science Centre. Through these partnerships, leading researchers have direct access to clinicians and patients and biotechnology companies, enabling scientific breakthroughs to reach the bedside more quickly and effectively than ever before. Figure 3. Translational Research Facility The new six-storey Translational Research Facility contains: A public café and seminar spaces on the ground floor A dedicated clinical trials floor with MRI and pharmacy A superfloor of platform technologies including cell therapies, bioinformatics, micro-imaging, medical genomics, mass spectrometry and clinical cell production facilities A dedicated floor for women s and children s research A boardroom and commercial partner Cartherics Pty Ltd occupies the top floor
5 5 Our Vision The vision of the Monash Health Translation Precinct (MHTP) partnership is to be a world leader in translational research, generating innovative scientific discoveries and revolutionising clinical care in a dynamic and collaborative environment. Our Purpose The MHTP: Is dedicated to translating medical research to improve healthcare Uses clinical insights to focus the agenda of basic research Is committed to innovative research development Enhances research collaboration locally, nationally and internationally Connects with industry and accelerates translation and adoption of discoveries Our Aims Develop the Precinct s capacity for world-leading innovative translational research Identify new opportunities for the translation of research into advances in healthcare Improve the health and wellbeing of the population Attract world-renowned research talent Encourage collaboration and partnerships between clinicians and researchers Optimise productive interactions between MHTP partners, industry and external stakeholders Increase efficiency by sharing resources and cutting edge platform technologies with researchers and industry partners Our Location The MHTP is based in Clayton, within the South-East Melbourne Innovation Precinct. Its location creates new opportunities for collaboration and commercialisation with some of Australia s leading research organisations and companies, including the Australian Synchrotron, the CSIRO and emerging biotechnology entities. Our Researchers Together we harness the combined research talents and innovation of over 500 scientific and clinical staff, including more than 200 postgraduate students, for basic and clinical research. We attract internationally recognised researchers, clinicians and collaborators to engage in research and innovative clinical practice development aligned to improve patient outcomes through early diagnosis, targeted and effective treatments as well as prevention of disease.
6 6 Our Focus Research undertaken at MHTP responds to national health priorities by focusing on health conditions and diseases recognised as having major social and economic impact. These include: 1. Cancer and Immune Stem Cell Therapies 2. Cardiovascular 3. Diabetes, Obesity, Men s Health and Endocrinology 4. Infectious and Inflammatory Diseases 5. Neuroscience and Psychiatry 6. Women s, Children s, and Reproductive Medicine (The Ritchie Centre) MHTP Technology Platform network To achieve the highest level of quality, the MHTP Partners have made significant investments in our technology capabilities that operate within a unified strategy, governance and quality framework. Several platforms have already achieved NATA accreditation promoting shared research and clinical utilisation. Access is available via a collaborative or fee-for-service model throughout the MHTP as well as to national scientific communities. Medical Genomics hosts a broad range of specialist genomic services that include Next Generation Sequencing, High Content Screening, Microarray, Real-Time qpcr and Fluidigm Single Cell technologies. The Medical Genomics core is fully integrated with the Monash Bioinformatics Platform for bioinformatic analysis and the Monash e-research for data processing and storage. Most recently, the Facility was awarded Australia s only Fluidigm Single Cell Centre of Excellence establishing strong collaborative ties with this world leading microfluidics and genomics company. Mass Spectrometry provides protein identification from samples such as SDS PAGE gel pieces, LC- MS/MS analyses for samples in solution or more complex samples such as cell or tissue lysates, accurate mass measurement for characterising recombinant proteins and identifying impurities and specialised sample fractionation techniques. The Facility provides a direct pathway to promote the translation of research findings from bench-to-bedside though collaboration and co-location with Monash Pathology s Biochemistry department. Flow Cytometry research flow cytometry capabilities are co-located with Monash Pathology s diagnostic flow laboratory promoting translational research activities. Through a partnership of Monash Pathology s Immunology and Clinical Haematology departments, more than 1500 Leukaemia, Lymphoma and Myeloma panels are performed annually to aid in the diagnosis and management of patients with suspected haematological neoplasms.
7 7 Histology offers both a Professional service provided by specialist staff, and a DIY service that provides access to laboratory facilities, specialist equipment and consumables. The Facility provides advice, training and research assistance and operates as a node of the Monash Histology Platform at Clayton Campus. Micro-Imaging provides consultation, instrumentation, services, training as well as collaborative research and project development in the areas of optical and fluorescence microscopy, confocal microscopy, live cell imaging and digital imaging and image analysis. The facility is also a part of the Monash Micro Imaging network, and as such has unfettered access to additional suites of imaging platforms, training, analysis and expertise located on the Monash University Clayton campus and Alfred Medical Research and Education Precinct. Animal Models Monash Medical Centre Animal Facilities (MMCAF) operates as an integral component of the Monash Animal Research Platform (MARP) dedicated to providing best welfare practices for all animals under our care whilst supporting the various scientific research groups at the MHTP. Monash Bioinformatics Platform has a wide range of expertise in biological research fields requiring cutting edge computational techniques such as genomics, proteomics and structural biology. Monash Biobank is an initiative established by Monash Health s Pathology department to support translational research through procurement of human samples. For more comprehensive details of platform capabilities, expertise and technologies, pleaser refer to MHTP Technology Platform brochure.
8 8 Clinical Translation (cgmp) Human Cell Therapy Facility The Miltenyi Biotec Cell Therapy Platform has been established to develop shared, cost effective facilities, capabilities and infrastructure for research and clinical translation to deliver accredited, cgmp compliant cellbased products and therapies to the clinic. It has been designed with a footprint of approximately 100sqm of Clean Room space and is situated on the Technology Platforms floor of the Translational Research Facility. Specialist equipment housed within this new Facility include: MACSQuant Tyto Cell Sorter co-located within this facility, the Tyto is a fully closed, droplet free, microchip-based 8-colour cell sorter capable of high-speed sorting under gentle conditions. CliniMACS Prodigy owned by Cartherics Pty Ltd, the Prodigy enables standardized and automated manufacture of gene modified T cells in a completely closed and sterile system. Figure 4. The CliniMACS Prodigy The Clean Room has been designed to achieve ISO Class 8 cleanliness specifications (AS/NZS ISO14644 Cleanrooms and associated controlled environments) and, as such, comply with TGA cgmp environmental requirements for the use of isolators for aseptic processing of human cells and tissue. The core of the Cell Therapy Platform is a unique ISO-5 ex-vivo cell processing chamber that has been developed with BioSpherix Ltd in the USA. This state-of-the-art unit will replace the need for expensive traditional ISO-5 Clean Rooms for cgmp activities and is ideally suited for small scale research and translation activities. Figure 5. BioSpherix setup within the Miltenyi Biotec Cell Therapy Platform
9 9 Cartherics Laboratories Located on Level 7 of the MHTP, the Cartherics Laboratories are fully equipped with the latest equipment and resources to enable our scientists to develop cutting edge technologies to fulfil the company s aim of stem-cell based off the shelf CAR-T cell products. Our team of dedicated, highly qualified and experienced scientists work directly under the supervision of the Chief Scientific Officer, Professor Richard Boyd, with guidance from the Chief Executive Officer, Professor Alan Trounson and a panel of Scientific and Corporate Advisors.
Personalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationOperations Department, Research Support Division
POSITION DESCRIPTION Position Details Position Title Department and Division Reports To WHS & Compliance Manager Operations Department, Research Support Division Chief Operating Officer The Institute The
More informationREMEDI. Regenerative Medicine Institute (REMEDI) NUI Galway, Ireland GENERAL PRESENTATION. Director: Prof. Frank Barry
Regenerative Medicine Institute (REMEDI) NUI Galway, Ireland Director: Prof. Frank Barry GENERAL PRESENTATION Contact person in NEWGEN: Dr. Jessica Hayes Working Group Involvement: Member of Working Group
More informationTranslational Medicine From Discovery to Health
Translational Medicine From Discovery to Health Jamal A. Ibdah, MD, PhD Sr. Associate Dean & Director, MU Institute for Clinical and Translational Science Translational Medicine Translational Medicine
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationTranslational Research
Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic
More informationOverview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
More informationMAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC
More informationSingHealth and A*STAR to advance medical research in diabetes; immunotherapy and drug development; and precision medicine
MEDIA RELEASE SingHealth and A*STAR to advance medical research in diabetes; immunotherapy and drug development; and precision medicine Strategic partnership sees Singapore s largest public healthcare
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationAustralia: A Dynamic Environment for Conducting Clinical Trials
Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors
More informationAn Taoiseach Opens New Research Centres to Benefit Frontline Patient Care
An Taoiseach Opens New Research Centres to Benefit Frontline Patient Care The clinical translational research facility will be a significant development for health care and medical technology sector in
More informationSmall Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre
Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Keith Williams Business Development Manager - Clinical Biotechnology Centre CBC - Aims and Objectives
More informationIBBL: Introduction to Biobanks and their services
IBBL: Introduction to Biobanks and their services HighTech meets Health, Oss (NL), 15 th June 2017 Monica Marchese, PhD Biomarker Validation Scientist AN ACCREDITED & CERTIFIED BIOBANK INFRASTRUCTURE FOR
More informationCLOSING DATE: 27 TH SEPTEMBER 2013
Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn POSITION: EXECUTIVE DIRECTOR, IRISH INSTITUTE OF PHARMACY CLOSING DATE: 27 TH SEPTEMBER 2013 EDUCATIONAL EXCELLENCE IN SURGERY MEDICINE
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationBIOMEDICAL RESEARCH CENTRES
Introduction BIOMEDICAL RESEARCH CENTRES The vision of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. This document sets out how the
More informationEUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008
Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is
More informationBridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society
Bridging the Gap Between Basic and Clinical Research Julio E. Celis Danish Cancer Society Barriers and Oportunities in Translational Research Promise of the new technologies What is Europe doing? Challenges
More informationBSc BIOMEDICAL SCIENCE
Overview College of Science Biomedical Science Core March 2017 (1) BSc BIOMEDICAL SCIENCE Biomedical Science Degree 2015 1 College of Science, NUI Galway Fullscreen Next page Overview [60 credits] [60
More informationGUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS
GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS 1. Introduction 1.1 This document provides guidance notes for the assessment of academic qualifications that have not been formally accredited
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationCould you help lead the NHS in your area?
Could you help lead the NHS in your area? Non-executive Director Candidate information pack Reference: S1666 We value and promote diversity and are committed to equality of opportunity for all and appointments
More informationRoche in Switzerland
Roche in Switzerland A leader around the world and at home Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche s three largest locations
More informationA & D Techeng A & D weighing A & D medical
A & D Australasia A & D Techeng A & D weighing A & D medical Excellence in measurement AND PROCESS SOLUTIONS. A&D AUSTRALASIA Originally founded in Australia in 1946, A&D Australasia (formerly Mercury
More informationImproving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre
Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 29/08/2013 Creating
More informationWorking together for better health. Partnering with Boehringer Ingelheim
Working together for better health Partnering with Boehringer Ingelheim Welcome to Boehringer Ingelheim Partnering Our vision Value through innovation is a reality A demonstrable history of innovation
More informationINFECTIOUS DISEASES WE ARE LEADING THE WAY.
INFECTIOUS DISEASES WE ARE LEADING THE WAY. NO1 WORLD S LARGEST COLLECTION OF TICK CELL LINES OF MEDICAL AND VETERINARY IMPORTANCE ONE OF THE BIGGEST COLLECTIONS OF TROPICAL VENOMOUS SNAKES IN THE COUNTRY
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationMARCH 15-16, 2018 PARIS PALAIS BRONGNIART. An event of PROGRAM
MARCH 15-16, 2018 PARIS PALAIS BRONGNIART An event of PROGRAM DIAGNOSIS - March 15, 12:15-13:15 Precision diagnostic: genomics plans panorama French genomic national plan: PFM2025 England Genome: 100 000
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationA unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
More informationINSTITUTE OF BIOMEDICAL SCIENCE
INSTITUTE OF BIOMEDICAL SCIENCE CORPORATE STRATEGY 2015-2018 Corporate Strategy 2015-2018 Page 1 of 8 Corporate Strategy 2015 2018 Vision, Mission and Values Our vision We aim to be the world s leading
More informationEuropean Technology Platform for Global Animal Health. Action Plan
European Technology Platform for Global Animal Health Action Plan European Technology T Platform for Global Animal Health Action Plan 2 Table of contents Executive Summary 7 Chapter 1: The Action Plan
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationNon-Executive Director
Non-Executive Director Appointment Brief Steelhouse Lane Birmingham B4 6NH Introduction Dear Candidate Thank you for your interest in the role of Non-Executive Director of Birmingham Women s and Children
More informationAdvanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None
EAHP March 2016 Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4 Dr. Lenka Taylor Pharmacy University Hospital Heidelberg Disclosure Relevant Financial Relationships
More informationCancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja
Cancer ImmunoTherapy Accelerator (CITA) Dr Shalini Jadeja The Vision To develop an integrative London initiative that emerges as the UK hub for immunotherapy of cancer focusing on: Safe and effective
More informationBSc Biomedical Science Degree
BSc Biomedical Science Degree Overview...2 BSc Biomedical Science...3 BSc Biomedical Science Pathway...4 BSc Biomedical Science Biochemistry Pathway...5 BSc Biomedical Science Pathway...6 BSc Biomedical
More informationClinical research in Southampton
Clinical and scientific excellence combined Clinical research in Southampton Clinical and scientific excellence combined Clinical research in Southampton is a partnership between University Hospital Southampton
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationThe postholder will work as a key member of the senior team for Organisational Learning and Development.
JOB TITLE: BAND: BASE: RESPONSIBLE TO: ACCOUNTABLE TO: OD Consultant AFC 8b XX Director of L&D and OD Director of L&D and OD JOB SUMMARY To provide specialist OD consultancy expertise and support to the
More informationEnabling research. excellence. Core research. facilities
Core research facilities Enabling research excellence Core research facilities Enabling research excellence Research & Prototype Foundry... 4 Sydney Cytometry... 6 Sydney Imaging... 8 Sydney Informatics
More informationIssues Brief 8 Employment and Skills
Issues Brief 8 Employment and Skills GROWING AUSTRALIA S EXTRAORDINARY TALENT Australia s innovative medicines industry is poised for growth. The strength of the medicines industry depends on the extraordinary
More informationTranslational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011
Translational Research through Public-Private Partnerships 65 th Annual Bohan Lecture Scott J. Weir, PharmD, PhD 08 October 2011 Drug Focused Translational Research Translational Research Defined by the
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationExam MOL3007 Functional Genomics
Faculty of Medicine Department of Cancer Research and Molecular Medicine Exam MOL3007 Functional Genomics Tuesday May 29 th 9.00-13.00 ECTS credits: 7.5 Number of pages (included front-page): 5 Supporting
More informationPathology Facilities and Potential for Collaboration. The University of Western Australia
Pathology Facilities and Potential for Collaboration UWA Pathology and Laboratory Medicine Pathology Research Themes Experimental pathology Infection and Immunity Translational pathology Cores Core Pathology
More informationThe Process Diagnostic. How to optimize the technology transfer and the development
The Process Diagnostic How to optimize the technology transfer and the development a does the on Introduction A critical aspect of industrialization is development. It is all about how to industrialize
More informationSolution Architect, Electronic Medical Record (EMR) Program Monash Health
Solution Architect, Electronic Medical Record (EMR) Program Monash Health A unique opportunity to drive workflow and solution design in Victoria s largest public health care organisation Play a key role
More informationIntegration of work flows for the generation of gene-modified cell products
Integration of work flows for the generation of gene-modified cell products Boro Dropulić, PhD, MBA Chief Science Officer and General Manager Lentigen Technology Inc., A Miltenyi Biotec Company Miltenyi
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationSTRATEGY FOR UK BIOTECHNOLOGY AND BIOLOGICAL SCIENCES INVITATION TO COMMENT. Introduction
STRATEGY FOR UK BIOTECHNOLOGY AND BIOLOGICAL SCIENCES INVITATION TO COMMENT Introduction The UK research and innovation landscape has changed considerably in recent years, and it continues to evolve with
More informationCentre for Microscopy, Characterisation and Analysis. Centre Director. Information for Candidates
Centre for Microscopy, Characterisation and Analysis Centre Director Information for Candidates Thank you for your interest in the position of Centre Director at The University of Western Australia (UWA).
More informationMolecular and Cell Biology (MCB)
Molecular and Cell Biology (MCB) Head of Department: Professor Michael Lynes Department Office: Room 104, Biology/Physics Building For major requirements, see the College of Liberal Arts and Sciences section
More informationThe University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Catalog Addendum
The University of Texas MD Anderson Cancer Center UTHealth 2016-2018 Catalog Addendum GSBS 2016-18 Catalog Addendum Table of Contents School Name Change... 1 Areas of Research Concentration Changes...
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationThe Seventh Framework Programme ( )
The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationBIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationLYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH. EN
LYSARC, ACADEMIC PARTNER OF LYMPHOMA CLINICAL RESEARCH EN www.lysarc.org THE LARGEST EUROPEAN ACADEMIC ORGANIZATION DEVOTED TO CLINICAL RESEARCH OPERATIONS IN THE LYMPHOMA FIELD Lymphoma is the 6th most
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationBachelor of Science (Hons) / Bachelor of Science Biomedical Science
Bachelor of Science (Hons) / Bachelor of Science Biomedical Science Awarded by In collaboration with This degree course is designed to give you a broad understanding of the scientific investigation of
More informationProgram overview. SciLifeLab - a short introduction. Advanced Light Microscopy. Affinity Proteomics. Bioinformatics.
Open House Program SciLifeLab Open House in Stockholm November 4, 2015 09:00-16:00 Contact: events@scilifelab.se Program overview 09:00-09:30-10:00-10:30-11:00-11:30-12:00-12:30-13:00-13:30-14:00-14:30-15:00-15:30-09:30
More informationMelbourne Australia. life sciences capital of the Asia-Pacific. A special supplement published by Life Science CLUSTERS Magazine
Melbourne Australia life sciences capital of the Asia-Pacific A special supplement published by Life Science CLUSTERS Magazine Message from the Minister for Innovation Focus for life sciences in the Asia-Pacific
More informationRegulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
More informationKinase Activity: a total solution
Kinase Activity: a total solution Protein arrays for multiplex kinetic measurements Robust Instrumentation User friendly software Kinetic data at your fingertips! PamGene s novel platform for profiling
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationFCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)
FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course BIOMARKERS AND ASSAY DEVELOPMENT February 6-10, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal The FCT
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationPosition description. Background. Department. Nature of environment. Baker Heart and Diabetes Institute
Position title: Payroll Officer Employer: Baker Heart and Diabetes Institute Department: Human Resources Supervisor/Manager: Payroll Manager Date: April 2018 Background The Baker Heart and Diabetes Institute
More informationBACKGROUNDER. Results of Genomics Technology Platforms 2016 Competition for Operations Support and Technology Development Funds
January 23, 2018 BACKGROUNDER Results of Genomics Technology Platforms 2016 Competition for Operations Support and Technology Development Funds Genome Canada and partners are pleased to invest approx.
More informationSt John Ambulance Australia SA Inc Annual Report 2011/12 Strategy
St John Ambulance Australia SA Inc Annual Report 2011/12 Strategy let me show you our strategy... Contents From the CEO 3 Executive summary 4 Key drivers 5 Key outcomes 6 2 From the CEO St John Ambulance
More informationChildren and Families Lead Scottish Government and Social Work Scotland Salary - circa 50k
Children and Families Lead Scottish Government and Social Work Scotland Salary - circa 50k This post is a collaboration between the Scottish Government and Social Work Scotland to provide policy support
More informationINNOVATION ALMOST 180 MILLION EUROS AREAS OF INNOVATION
From health to beauty INNOVATION IMAGINING FUTURE PRODUCTS 40 Investments in R&D reflect the importance that we attach to the discovery and development of innovative therapeutic and well-being solutions,
More informationAccount Manager. Information for candidates
Information for candidates Our mission We raise money so that Great Ormond Street Hospital can provide world-class care for its young patients and their families, and to pioneer new treatments and cures
More informationSINGAPORE SCIENTISTS DEVELOP DNA-ALTERING TECHNOLOGY TO TACKLE DISEASES Finding could lead to new therapeutics for diseases
MEDIA RELEASE FOR IMMEDIATE RELEASE 13 SEPTEMBER 2016 SINGAPORE SCIENTISTS DEVELOP DNA-ALTERING TECHNOLOGY TO TACKLE DISEASES Finding could lead to new therapeutics for diseases SINGAPORE Researchers in
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationBiomedical Science and Biology. Undergraduate Degree Programmes
Biomedical Science and Biology Undergraduate Degree Programmes Biomedical Science and Biology Welcome to Biomedical Science and Biology at Aston You are about to start one of the most exciting experiences
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationStem Cell Principle -
Effective Date: 31.10.2017 Doc ID: 20290214 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Stem Cell Principle - Rationale Research on human stem cells and their
More informationNATIONAL INSTITUTE OF ANIMAL BIOTECHNOLOGY (NIAB)
Advertisement No 1/2014 NATIONAL INSTITUTE OF ANIMAL BIOTECHNOLOGY (NIAB) (An Autonomous Institute of the Dept. of Biotechnology, Ministry of Science & Technology, Government of India) D. No. 1-121/1,
More informationnucleus network. australia s clinical research centre. company report 2006
nucleus network. australia s clinical research centre. company report 2006 company report 2007 01 nucleus network has now fulfilled its objective of providing a clinical trials platform for victoria with
More informationThe Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview
The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview Mission: The mission of The Endocrine Society is to advance excellence in endocrinology and promote
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More information